Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOEME: Akynzeo for antiemetic prophylaxis in endometrial cancer on taxane–platinum chemotherapy
2023-504150-35-00Phase 4Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of palonosetron in endometrial cancer (EC) and chemotherapy-induced nausea and vomiting (CINV), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Complete response during overall phase (cycle 1). Planned start Nov 2023; status: authorised.
02
Drugs
palonosetron
03
Conditions
endometrial cancer (EC)chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2023-504150-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504150-35-00.